Bioinno Secures ￥100M in Series Pre-A Funding

(VCBeat) Feb. 23, 2021 -- Beijing Bioinno Technology Co., Ltd. ("Bioinno") has announced today announced the closing of a Series Pre-A round of funding worth nearly one hundred million yuan, co-led by Tigermed and TigerYeah Capital, with participation from Shanghai Orient Securities Capital, Fuying Investment, TENEDGE, Qianhui Zhitou Capital, and Huiji Investment. Chana Capital and WinX Capital acted as financial advisors in the latest round.

The funds raised are earmarked for the construction of Bioinno's R&D and production base in Suzhou Taicang, talent recruitment, etc.

Prior to this, Bioinno had raised over 10 million yuan in its angel round of financing in July 2020 from TigerYeah Capital and several strategic shareholders.

Founded in late 2019, Bioinno is an international CDMO company in the biomedical field. It can not only provide services including construction and screening of cell lines, process development, clinical material production, clinical application, GMP compliant manufacturing of listed products, and supply chain management, but also can produce supply-chain-related products, such as the internationally first-class engineered cells and cell culture media. Bioinno has established a complete supply system, which can ensure the efficient, high quality, and stable provision of CDMO services under the premise of effective cost control.

Dr. Zhao Xiaojian, chairman and CEO of Bioinno, is a leading scientist in cell culture and a biological pharmaceutical expert. He once served as the Technical Director of Invitrogin (Thermofisher's subsidiary, a global leader of culture media) and Merck-Milliore, where he developed dozens of high-end serum-free culture medium and additive products that are currently popular in the world. Dr. Zhao has accumulated decades of experience in biomedical research and development and production.

Tigermed is a contract research organization providing the whole process clinical trial services for the research and development of pharmaceutical products. Since its inception, the company is dedicated to the provision of medical research and development services that enables clients to reduce the risk and cost of R&D, while advancing the process of marketization.

Founded in 2014, TigerYeah Capital is dedicated to build itself as a famous brand in the healthcare investment field and become a top-tier investment firm.  TigerYeah Capital focuses on early and growing equity investment in healthcare, especially in the field of the Medical Device, Health Food, CRO, and Health Services. By leveraging Tigermed solid platform and TigerYeah's abundant industrial resources,  TigerYeah Capital provides comprehensive post-investment services for entrepreneurs.